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Abstract Expression pattern and immunogenicity are
critical issues that deWne tumor antigens as diagnostic
markers and potential targets for immunotherapy. The
development of SEREX (serological analysis of recom-
binant expression libraries) has provided substantial
progress in the identiWcation of tumor antigens eliciting
both cellular and humoral immune responses in cancer
patients. By SEREX, we have previously identiWed
RAB38/NY-MEL-1 as a melanocyte diVerentiation anti-
gen that is highly expressed in normal melanocytes and
melanoma tissues but not in other normal tissues or can-
cer types. In this study, we further demonstrate that
RAB38/NY-MEL-1 is strongly immunogenic, leading to
spontaneous antibody responses in a signiWcant propor-
tion of melanoma patients. The immune response occurs
solely in malignant melanoma patients and was not
detected in patients with other diseases, such as vitiligo,
aVecting melanocytes. Fine analysis of the spontaneous
anti-RAB38/NY-MEL-1 antibody response reveals a
polyclonal B cell recognition targeting various epitopes,
although a dominant immunogenic region was preferen-
tially recognized. Interestingly, our data indicate that
this recognition is not rigid in the course of a patient’s
response, as the dominant epitope changes during the
disease evolution. Implications for the understanding of
spontaneous humoral immune responses are discussed.
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Humoral immune responses directed against tumor
antigens are frequently observed in cancer patients,
reXecting the interaction between the immune system
and developing tumors. The properties of self-antigens
necessary to induce immune responses speciWc to can-
cer are still poorly deWned. Genetic aberrations [4, 27,
29], changes in the level of gene expression [22, 30], or
aberrant expression in tumor lesions [23, 26] have been
shown as potential mechanisms for immunogenicity,
and serological responses against these antigens have
been reported in cancer patients. In the last decade, the
development of novel immunological methods has
greatly contributed to our understanding of serological
autologous immune responses in tumor patients (for a
review, see [10]). SEREX (serological analysis of
recombinant expression libraries), in particular, an
expression cloning strategy, has led to the deWnition of
a large repertoire of immunogenic antigens in various
tumor types [24]. Ideally, this technique distinguishes
antigens with a direct relevance to cancer etiology or
cancer progression from antigens that represent gen-
eral autoimmunogenic cellular components and pro-
vides attractive antigenic targets for immunotherapy
approaches in cancer patients.
Among the SEREX-deWned repertoire of tumor
antigens, cancer-testis (CT) antigens and diVerentia-
tion antigens have been of particular interest with
respect to immunotherapy strategies in cancer [28].
The Wrst category of antigens (e.g. NY-ESO-1, MAGE,
SSX-2, etc.) are expressed in normal adult tissues
solely in testis, but are present/activated in a variety of
diVerent tumor types in a lineage-unrestricted fashion.
In contrast, diVerentiation antigens, e.g. Melan-A/
MART1, tyrosinase, and gp100, are expressed in tis-
sues and tumors of a particular cell lineage such as
melanocytes. Melanocyte diVerentiation antigens fre-
quently induce speciWc serological and T cell responses
in melanoma patients [5, 7, 12, 32].
In a previous SEREX screening of a melanoma cell
line library, we identiWed RAB38/NY-MEL-1 (later
RAB38) [9], a polypeptide of 211 amino acids resem-
bling a new member of the rab family of G proteins
(for a review, see [21]). Preliminary data indicate a
highly regulated expression that is restricted to the
melanocytic cell lineage [9]. Similar to most other mel-
anosomal proteins, a coat color defect mapping to the
RAB38 genetic locus has recently been identiWed in
the mouse system [16]. In addition to Wve highly con-
served regions necessary for GTP binding, the struc-
tural features are characterized by a unique COOH
terminus which allows post-translational lipid modiW-
cations. Interestingly, intracellular localization of a rat
homolog with 97% amino acid identity indicates that
RAB38 is expressed extensively in the cytoplasm with
a distribution pattern similar to the endoplasmic reticu-
lum [18, 19].
In this study, we further analyzed the expression
pattern and immunogenicity of RAB38. As antici-
pated, RAB38 exhibits the characteristics of a melano-
cyte diVerentiation antigen as it is abundantly
expressed in normal melanocytes and melanoma and
not in any other normal tissues or non-melanocytic
tumor. Spontaneous humoral immune responses
against RAB38 are characterized by (i) their presence
in a large proportion of melanoma patients, (ii) their
restriction to patients with melanoma but not other
tumor types, and (iii) polyclonal responses targeting
various epitopes with a dominant immunogenic region
identiWed. The restricted expression pattern and the
immunogenicity of this antigen suggest that RAB38
may be used as a marker protein and as an appropriate
target for antigen-speciWc immunotherapy in patients
with malignant melanoma.
Materials and methods
Sera, tumor samples, and melanoma cell lines
Twelve metastatic melanoma lesions derived from 10
melanoma patients, and serum samples from 52
melanoma patients, 15 non-melanoma cancer patients,
13 vitiligo patients, and 15 healthy individuals were
obtained at the University Hospital, Zurich, Switzer-
land, and Krankenhaus Nordwest Frankfurt, Germany,
under consideration of local legal regulations. Mela-
noma cell lines were derived from the repository of the
Ludwig Institute for Cancer Research, New York
Branch at Memorial Sloan-Kettering Cancer Center.
RNA extraction and real-time RT-PCR
Total RNA was extracted from melanoma lesions by
the Qiagen RNA Extraction Kit (Qiagen, Hom-
brechtikon, Switzerland) and quantiWed by spectros-
copy (SmartSpec 3000 Spectrophotometer, BioRad).
In addition, RNA was obtained from 16 diVerent
normal tissues (Clontech, Basel, Switzerland) and
cultured human melanocytes (Gentaur). RNA was
reverse-transcribed into cDNA using the TaqMan EZ
RT-PCR kit (Applied Biosystems, Rotkreuz, Switzer-
land). Gene-speciWc TaqMan probes with a predeter-
mined, optimum concentration of gene-speciWc forward
and reverse primers (300–900 nM) were purchased123
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Assay on Demand). For endogenous control, 18S
RNA-speciWc primers/probes were purchased from
Applied Biosystems. The PCR consisted of 40 cycles of
95°C denaturation (15 s) and of 60°C annealing/exten-
sion (60 s). A total of 20 ng/l were reverse-transcribed
and 2.5 l of cDNA was diluted in TaqMan Universal
PCR Master Mix supplemented with (Fam)-labeled
gene-speciWc TaqMan probe, and an optimal concen-
tration of the gene-speciWc forward and reverse prim-
ers (300–900 nM) were used for PCR. All PCR
reactions were run as triplicates, and thermal cycling
and Xuorescent monitoring were performed using an
ABI7000 thermal cycler (Applied Biosystems).
Production of the recombinant RAB38 protein
The entire coding region of RAB38 (636 bp) was
ampliWed with primers including speciWc cleavage sites
for BamH1 (Bam-5: CACACAGGATCCATGCA
GGCCCCGCACAAGGAG) and HindIII (Hind-3: C
ACACAAAGCTTCTAGGATTTGGCACAGCCA
GAG). After digestion with BamH1 and HindIII, the
PCR product was cloned into the pQE30 expression
vector (Qiagen). Competent M15 (pREP4) Escherichia
coli were transformed and the recombinant protein
was produced and puriWed under denaturing condition
following the manufacturer’s protocol. The puriWed
recombinant His-tag protein was analyzed by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE), followed by silver staining.
Detection of RAB38-speciWc antibody responses
For Western blot assays, the puriWed recombinant pro-
tein and lysate of a RAB38-expressing melanoma cell
line (SK-MEL-37) resuspended in 1:2 in Laemmli sam-
ple buVer and denaturated for 5 min at 95°C were used.
1D SDS–PAGE was performed on 15% acrylamide gel.
The protein was then transferred onto Protan Nitrocel-
lulose Membranes (Schleicher and Schuell, BioScience,
Dassel, Germany) in a Mini Trans-Blot cell (BioRad).
The eYciency of the electrotransfer was assessed by
Ponceau Red staining of the membranes. After incuba-
tion with patients’ sera diluted at 1:250 for 60 min,
reactivity was determined using an AP-conjugated goat-
anti-human IgG-speciWc antibody (Jackson Immuno
Research Laboratories, LaRoche, Switzerland) diluted
1:5,000. Immunoreactive proteins were visualized with
BCIP and NBT (Roche, Rotkreuz, Switzerland). All
steps were performed at room temperature.
For ELISA assays, 96-well plates (Corning, Wohlen,
Switzerland) were coated with 50 ng of recombinant
RAB38 protein, tetanus toxoid (Berna), or overlap-
ping peptides of 18 aa length derived from the RAB38
protein sequence (BioSynthesis, Lewisville, TX, USA).
All peptides were diluted in PBST (PBS/0.5% Tween-
20). Plates were incubated overnight at 4°C and con-
secutively blocked with PBST/5% fetal calf serum
(FCS) for 2 h at 4°C and then washed twice. Serum
samples diluted 1:250 in PBST/5% FCS were incubated
for 2 h at room temperature, followed by incubation
for 30 min with a secondary, peroxidase-conjugated,
goat-anti-human IgG antibody (Sigma, Darmstadt,
Germany), diluted 1:20,000 in PBST/5% FCS. The
plates were subsequently developed at room tempera-
ture for 30 min with 150 l/well tetramethylbenzidine
(Sigma, Darmstadt, Germany) and analyzed using an
ELISA reader (Labexim LMR1) at  = 450 nm.
Immunohistochemistry
Tissues were mounted in OCT, snap-frozen in isopen-
tane pre-cooled liquid nitrogen upon surgical removal.
Five micrometers thick frozen tissue sections were
placed on glass slides, air-dried, Wxed with cold ace-
tone for 10 min, and stored at ¡70°C. As a positive
control, melanoma cell line SK-MEL-37 grown in slide
chambers was used. After removal of media, cells
were air-dried and Wxed with cold acetone (data not
shown). Slides were incubated with aYnity-puriWed
polyclonal rabbit anti-RAB38 antibodies [18, 19],
diluted 1:200 in TBS for 30 min at room temperature.
Primary antibodies were detected with a goat anti-
rabbit secondary, followed by alkaline phosphatase
labeled donkey antibodies to goat immunoglobulins
(Jackson ImmunoResearch Laboratories). Dilutions
of secondary reagents were made in TBS containing
1% FCS. Alkaline phosphatase was then detected by a
red color reaction using naphthol AS-BI phosphate as
a substrate and new fuchsin as a chromogen. Endoge-
nous alkaline phosphatase was blocked by levamisole.
Slides were counterstained with Meyer’s hematoxylin
for 2 min.
Prediction of the protein structure and B cell epitopes
Hydrophilicity was calculated based on the Kyte–Doo-
little [14] method with a window size of 17 amino acid
residues. Surface accessibility and buried residues were
calculated using the ExpASy (Expert Protein Analysis
System) with a window of 17 amino acid residues [20].
To visualize potential binding sites depending on the
3D structure, the protein sequence was blasted against
the pdb database [1]. 3D graphs were designed using
the RasMol software Version 2.6.123
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RAB38 mRNA expression in normal tissues and 
melanomas
Extending our previously reported data [9], we quanti-
Wed mRNA expression in a panel of diVerent normal
tissues and melanoma lesions by real-time RT-PCR.
The analysis of normal tissues is shown in Fig. 1a. Rel-
ative to the mRNA level in normal melanocytes,
which was arbitrarily set as 100%, the adrenal gland
showed a weak expression of RAB38 mRNA (4%),
whereas all other normal tissues revealed a marginal
(·1%) to absent RAB38 mRNA expression. In con-
trast, 10 out of 12 metastatic melanoma lesions
expressed RAB38 transcripts (Fig. 1b). In particular,
four lesions (ZH-104, ZH-23a, ZH-174, and ZH-122a)
showed strong overexpression of RAB38 mRNA up
to 22-fold compared to that of melanocytic expression;
Wve melanoma lesions (ZH-23b, ZH-122b, ZH-132,
ZH-167, and ZH-274) had RAB38 mRNA levels simi-
lar to melanocytes. Two metastatic lesions (ZH-346
and ZH-256) showed no signiWcant RAB38 mRNA
expression and were derived from an amelanotic mel-
anoma and an uveal melanoma. In agreement with the
common phenomenon of heterogenous tumor antigen
expression, we noticed variable expression levels of
RAB38 mRNA in diVerent metastases derived from
the same patient (ZH-23a vs. ZH-23b and ZH-122a vs.
ZH-122b).
RAB38 protein expression in malignant melanoma
Owing to a high homology to the rat rab-related pro-
tein, sharing 97% amino acid identity, an aYnity-
puriWed rabbit anti-rat polyclonal RAB38 antibody
[18, 19] was used to stain human melanoma lesions.
Immunostaining of melanoma cell line SK-MEL-37
(Fig. 2a) and melanoma lesions (ZH-122b and ZH-23b;
Fig. 2b, c, respectively) showed cytoplasmic immunore-
activity in RAB38-positive melanoma cells. Level of
RAB38 transcripts, as determined by real-time PCR,
correlated with the immunostaining results: ZH-122b,
which showed RAB38 mRNA level of about 90% com-
pared to human melanocytes, revealed homogeneous
immunostaining, whereas ZH-23b (expression level of
40% of melanocytes) showed more restricted immu-
nopositivity. No staining was present in melanoma ZH-
241 that was RAB38-negative by real-time RT-PCR
(Fig. 2d). No staining was present in surrounding non-
melanocytic tissue components such as stroma, kerati-
nocytes, smooth muscle cells, connective tissue cells,
and endothelial cells (Fig. 2b).
Melanoma patients frequently develop humoral 
immune responses against RAB38
RAB38 was previously identiWed in a SEREX analysis
of an autologous melanoma cell line library [9]. To fur-
ther assess the frequency and speciWcity of anti-RAB38
humoral responses, we screened 95 sera derived from
52 melanoma patients, 15 non-melanoma cancer
patients, 13 vitiligo patients, and 15 healthy individuals
for anti-RAB38 antibodies by ELISA. Sera from
healthy individuals allowed the deWnition of a cut-
oV value (0.271), deWned as the mean OD plus
3£ standard deviations (0.22§3£0.017). To assess the
general immune competence of the individuals ana-
lyzed, vaccine-induced humoral immune responses
against a recombinant tetanus toxoid protein were
tested. The frequency of tetanus-toxoid-speciWc anti-
body responses was not signiWcantly diVerent in mela-
noma patients vs. non-melanoma cancer patients or
non-cancer patients, respectively (61% vs. 87 or 87%;
p > 0.05, Fig. 3a). This frequency is also well compatible
Fig. 1 RAB38 cDNA-speciWc real-time RT-PCR analysis of 16
normal tissues (a) and 12 melanoma lesions obtained from
patients with malignant melanoma (b). The data are expressed
relative to the mRNA level in normal melanocytes, arbitrarily set
as 100%. The value of each sample was determined in triplicate
reactions. NTC no template control
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Cancer Immunol Immunother (2007) 56:249–258 253with previously reported data [25]. In contrast, anti-
RAB38 antibodies were detected exclusively in sera
derived from melanoma patients. All non-melanoma
cancer patients, vitiligo patients, and healthy individu-
als were tested negative. RAB38-speciWc antibodies
were detected in 12 out of 52 sera (23%) derived from
melanoma patients (Fig. 3b), with titers ranging from
1:100 to 1:1,000 (data not shown). Some positive sera in
ELISA assays were conWrmed by Western blotting
(data not shown). SpeciWcity of these antibodies was
demonstrated by testing antibody-positive sera against
the recombinant RAB38 protein as well as a RAB38-
positive melanoma cell line lysate (SK-MEL-37) by
Western blotting (Fig. 3c, d). A protein species migrat-
ing at approximately 23 kDa was recognized in both
lanes, conWrming the speciWc immunoreactivity.
IdentiWcation of RAB38 epitopes recognized 
by antibodies present in melanoma sera
To further explore antibody epitopes and immuno-
genicity of antigenic sites within the RAB38 protein,
reactivity of patients’ sera was tested against 25 over-
lapping peptides of 18 amino acid residues that span
the entire RAB38 protein sequence. Background reac-
tivity against the peptides was determined using the
sera from three healthy individuals, calculated as mean
OD plus 3 £ standard deviations (ODcontrol). Samples
with OD values ¸2-fold above the background were
considered positive. Sera derived from seven RAB38
antibody-positive melanoma patients (NW-2231, ZH-
48, NW-37, NW-1274, MZ-19-MEL, ZH-104, and NW-
1751) were used for epitope mapping and the results
were shown in Fig. 4. Sera from melanoma patients
showed signiWcant reactivity with distinct peptides
within the RAB38 protein sequence. In particular,
reactivity against the amino terminal part (aa 41–58)
and the central part (aa 73–114) was observed in three
of the seven patients (ZH-48, ZH-104, and NW-2231)
and four of the seven patients (ZH-48, NW-37, NW-
1751, and NW-2231), respectively. All patients’ sera
showed reactivity against peptide sequences in the car-
boxy terminus. Notably, all seven sera recognized at
least peptide 20 and/or peptide 21, indicating that the
represented segment (aa 153–178) is preferentially
antigenic. However, reactivity was not restricted to
those sites, as other regions were also recognized, but
at lower frequencies. To conWrm the potential immu-
nogenicity of the RAB38 region represented by pep-
tides 20 and 21 (aa 153–178), we performed a computer
prediction analysis based on hydrophilic proWles using
the Kyte–Doolittle method [14]. We identiWed several
hydrophilic regions within the amino acid sequence of
RAB38 (Fig. 5a), which tend to localize on the surface
of the molecule. Additionally, applying the ExpASy
program, we were able to predict the sequences
exposed on the surface of the RAB38 protein (Fig. 5b)
as well as the sequences buried to the interior of the
Fig. 2 Immunohistochemical 
staining of a melanoma cell 
line (SK-MEL-37, a) and 
three melanoma lesions 
(ZH-122b, b; ZH-23b, c; and 
ZH-241, d) using a polyclonal 
RAB38 antibody [18, 19]. 
MagniWcation: £40 (a–d)123
254 Cancer Immunol Immunother (2007) 56:249–258protein (Fig. 5c). Importantly, only the region aa 153–
178 recognized by all seven patients’ sera was predicted
to be both accessible and hydrophilic. Figure 5d visual-
izes the preferential antigenic region on a 3D structure
of the RAB38 protein. To assess the epitope proWle of
individual patients over the course of the disease, fol-
low-up sera from two seropositive patients were tested.
Figure 6 shows a stable antibody titer against the
RAB38 protein over 3 years for patient NW-37 and
7 months for patient NW-1274 (Fig. 6a, b). Although
the antibody titer against the recombinant protein
remains stable, a switch of the predominant epitope
was observed for patient NW-1274 (Fig. 6c). In com-
parison, the epitope proWle for patient NW-37
remained stable over more than 3 years (Fig. 6d).
Discussion
The recognition of tumor cells by the immune system is
reXected by spontaneous cellular and humoral immune
responses. The immune system can target and destroy
tumor cells via the recognition of speciWc tumor anti-
gens [3]. Promising target antigens for immunothera-
peutic approaches are tumor-restricted immunogenic
proteins that are expressed at high levels in malignant
Fig. 3 Tetanus-toxoid-spe-
ciWc (a) and RAB38-speciWc 
antibody responses (b) in sera 
from melanoma patients, non-
melanoma cancer patients, 
healthy donors, and vitiligo 
patients evaluated in ELISA 
assays using the recombinant 
RAB38 and tetanus toxoid 
protein, respectively. The 
dashed line indicates a cut-oV 
value (i.e. mean 
OD § 3 £ standard devia-
tions), as determined in 
ELISA assays with the recom-
binant RAB38 protein using 
sera from healthy individuals. 
To determine the speciWcity of 
RAB38 antibody-positive 
sera from melanoma patients, 
the recombinant RAB38 
protein (c) and lysate of a 
RAB38-positive melanoma 
cell line (SK-MEL-37, d) were 
transferred onto nitrocellu-
lose membranes and probed 
with sera from RAB38 anti-
body-positive melanoma 
patients (NW-37, ZH-48, and 
NW-1274) and healthy donors 
(Z-S-75, Z-S-79, and Z-S-80)
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Cancer Immunol Immunother (2007) 56:249–258 255cells. A growing number of tumor antigens have been
identiWed by methods based on autologous T cell
responses and serological responses in cancer patients.
To date, only few of these antigens, e.g. NY-ESO-1,
have been reported to frequently elicit spontaneous
cellular as well as humoral immune responses. Like
RAB38, the CT antigen NY-ESO-1 was initially identi-
Wed based on a spontaneous antibody response
employing the SEREX method [2]. Interestingly, most
NY-ESO-1 seropositive patients have simultaneous
NY-ESO-1-speciWc CD8 and CD4 T cell responses
[6, 11]. This observation supports the strategy of
exploiting serological responses in order to identify
relevant T cell epitopes that can be used as targets for
vaccine-based immunotherapy. Ideal target antigens
should exhibit a frequent and tumor-restricted expres-
sion as well as a high immunogenicity, as reXected by
frequent spontaneous immune responses in patients
with antigen-positive tumors.
Here we report on RAB38, a novel melanocyte diVer-
entiation antigen, that frequently induces humoral
immune responses in melanoma patients. Extending the
initial expression analysis by northern blot [9], we
performed real-time RT-PCR in normal tissues and
melanoma lesions, and conWrmed the tissue-restricted
expression of RAB38 with predominant expression in
melanocytes and in melanoma tissues. The low-level
mRNA expression in adrenal gland needs to be
conWrmed in a higher number of cases and especially
Fig. 4 Detection of antibodies against single RAB38-derived
peptides. Sera from melanoma patients with humoral immune
responses against RAB38 (NW-2231, ZH-48, NW-1274, MZ-10-
MEL, ZH-104, and NW-1751) were tested in ELISA assays using
overlapping peptides that span the entire RAB38 protein
sequence (see Materials and methods). Background reactivity
against the peptides (i.e. mean OD § 3 £ standard deviations)
was determined in ELISA assays using sera from healthy individ-
uals. Samples with OD values ¸twofold above the background
were considered positive
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Fig. 5 Computer-aided prediction of B cell epitopes from
RAB38. a The hydrophilicity score of the RAB38 protein was cal-
culated with Kyte–Doolittle method [14]. Using a window size of
17 amino acid residues, the RAB38 protein was predicted for
surface accessibility (b) and buried residues (c). Localization of
the immunodominant region (aa 153–178) within the predicted
3D structure of the RAB38 protein (d)
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256 Cancer Immunol Immunother (2007) 56:249–258on a protein level. However, like melanocytes, adrenal
medulla is a neuroectodermal tissue and some relation
between both tissues may exist. Among the melanomas
of our series, the only negative cases were specimens
of an amelanotic melanoma and uveal melanoma.
Amelanotic melanoma is characterized by the low
number of melanosomes which may explain the low
expression of some melanocyte diVerentiation
antigens. However, on a protein level, melanocyte
diVerentiation antigens such as Melan-A, gp100,
and tyrosinase did not show a lower expression in
amelanotic melanoma. The biology of uveal melanoma
is poorly understood and it has been reported that
the expression of melanocyte lineage markers diVers
from cutaneous melanoma [8] (E. Jaeger, personal
communication). RAB38 mRNA expression data
obtained by real-time RT-PCR correlated to RAB38
protein expression analyzed by immunohistochemistry
using a polyclonal rabbit anti-rat RAB38 antibody.
RAB38-positive cells showed cytoplasmatic staining
Fig. 6 RAB38-speciWc antibody responses in individual patients
over the course of the disease. Sera of two melanoma patients
NW-37 (a, c) and NW-1274 (b, d) were tested in ELISA assays
using the recombinant RAB38 protein (a, b) and overlapping
peptides as mentioned above (c, d)
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Cancer Immunol Immunother (2007) 56:249–258 257which is in line with previous reports localizing murine
RAB38 to the melanosomal compartment in mice [16].
We are currently generating mAbs to human RAB38
in order to analyze its protein expression in normal tis-
sues and tumors.
In addition to its tumor-restricted expression, we
demonstrated that RAB38 is highly immunogenic in
melanoma patients. Spontaneous RAB38-speciWc anti-
body responses were present in 23% of melanoma
patients (12 out of 52). As not all melanomas express
RAB38, the frequency of anti-RAB38 response in
patients with RAB38-positive melanoma is likely to be
higher. The immune response was present solely in
melanoma patients and none of the 13 vitiligo patients
had detectable RAB38-speciWc antibodies. This sug-
gests that serological responses to RAB38 likely result
from ongoing interactions of the immune system with
evolving and progressing tumors, rather than a tumor-
unrestricted process following cell necrosis and release
of intracellular proteins. However, this does not exclude
the possibility of side eVects such as vitiligo as a result
of immune responses to RAB38 vaccines as it has been
observed in clinical trials using vaccines to other mela-
nocyte diVerentiation antigens such as Melan-A and
tyrosinase [13, 17].
To identify antibody epitopes within the RAB38
sequence, we tested RAB38 antibody-positive sera
against RAB38-derived peptides in ELISA assays and
correlated the serological Wndings with the results of
computer algorithms predicting potential immuno-
genic sites in the protein structure [15, 20]. The results
of both methods concurred indicating an immunodom-
inant region encompassing position aa 153–178. Nota-
bly, this dominant B cell epitope may by used to
measure antibody responses, as previously reported for
NY-ESO-1 [31]. This would bypass the requirement
for puriWcation of the recombinant protein which is
often diYcult to achieve. However, as demonstrated
here, a potential caveat of the peptide-based approach
for measuring antibodies is the possibility of changing
the epitope during the course of the disease (Fig. 6c).
Consequently, changing epitopes may simply be
missed in epitope-restricted assays. Moreover, the
present approach is not suitable for the identiWcation
of conformational epitopes.
In conclusion, the present data support our initial
analyses and demonstrate that RAB38 is a true mela-
nocyte diVerentiation antigen which may be useful for
diagnostic purposes or may serve as a target for immu-
notherapy of melanoma. Further studies about the pro-
tein expression and potential T cell responses are
necessary and underway to assess the role of RAB38
as a cancer target and diagnostic marker.
Acknowledgments This work was supported in part by a Swiss
National Science Foundation special program, and a grant from
the Cancer Research Institute/Ludwig Institute for Cancer
Research Cancer Vaccine Collaborative, the Terry-Fox, Hanne-
Liebermann and Claudia-von-Schilling Foundation, and the UBS
Wealth Management. A.Z., A.G., and S.W. were supported in
part by the Emmy-Noether Program (Zi685-2/3) of the Deutsche
Forschungsgemeinschaft. The excellent technical assistance of
Claudia Frei and Julia Karbach is greatly appreciated.
References
1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN,
Weissig H, Shindyalov IN, Bourne PE (2000) The protein
data bank. Nucleic Acids Res 28:235–242
2. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang
S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997)
A testicular antigen aberrantly expressed in human cancers
detected by autologous antibody screening. Proc Natl Acad
Sci USA 94:1914–1918
3. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology
of cancer immunosurveillance and immunoediting. Immunity
21:137–148
4. Fensterle J, Becker JC, Potapenko T, Heimbach V, Vetter
CS, Brocker EB, Rapp UR (2004) B-Raf speciWc antibody
responses in melanoma patients. BMC Cancer 4:62
5. Fishman P, Merimski O, Baharav E, Shoenfeld Y (1997)
Autoantibodies to tyrosinase: the bridge between melanoma
and vitiligo. Cancer 79:1461–1464
6. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar
A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, et al
(2003) Survey of naturally occurring CD4+ T cell responses
against NY-ESO-1 in cancer patients: correlation with anti-
body responses. Proc Natl Acad Sci USA 100:8862–8867
7. Huang SK, Okamoto T, Morton DL, Hoon DS (1998) Anti-
body responses to melanoma/melanocyte autoantigens in
melanoma patients. J Invest Dermatol 111:662–667
8. Iwamoto S, Burrows RC, Grossniklaus HE, Orcutt J, Kalina
RE, Boehm M, Bothwell MA, Schmidt R (2002) Immunophe-
notype of conjunctival melanomas: comparisons with uveal
and cutaneous melanomas. Arch Ophthalmol 120:1625–1629
9. Jager D, Stockert E, Jager E, Gure AO, Scanlan MJ, Knuth
A, Old LJ, Chen YT (2000) Serological cloning of a melano-
cyte rab guanosine 5-triphosphate-binding protein and a
chromosome condensation protein from a melanoma com-
plementary DNA library. Cancer Res 60:3584–3591
10. Jager D, Taverna C, Zippelius A, Knuth A (2004) IdentiWca-
tion of tumor antigens as potential target antigens for immu-
notherapy by serological expression cloning. Cancer
Immunol Immunother 53:144–147
11. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J,
Neumann A, Rieckenberg J, Chen YT, Ritter G, et al (2000)
Induction of primary NY-ESO-1 immunity: CD8+ T lympho-
cyte and antibody responses in peptide-vaccinated patients
with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198–
12203
12. Jager E, RinghoVer M, Arand M, Karbach J, Jager D, Ilse-
mann C, Hagedorn M, Oesch F, Knuth A (1996) Cytolytic T
cell reactivity against melanoma-associated diVerentiation
antigens in peripheral blood of melanoma patients and
healthy individuals. Melanoma Res 6:419–425
13. Kemp EH, Waterman EA, Weetman AP (2001) Immunolog-
ical pathomechanisms in vitiligo. Expert Rev Mol Med
2001:1–22123
258 Cancer Immunol Immunother (2007) 56:249–25814. Kyte J, Doolittle RF (1982) A simple method for displaying
the hydropathic character of a protein. J Mol Biol 157:105–
132
15. Lins L, Thomas A, Brasseur R (2003) Analysis of accessible
surface of residues in proteins. Protein Sci 12:1406–1417
16. Loftus SK, Larson DM, Baxter LL, Antonellis A, Chen Y,
Wu X, Jiang Y, Bittner M, Hammer JA III, Pavan WJ (2002)
Mutation of melanosome protein RAB38 in chocolate mice.
Proc Natl Acad Sci USA 99:4471–4476
17. Merimsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigel-
man R, Cohen-Aloro D, Fishman P (1996) Anti-tyrosinase
antibodies in malignant melanoma. Cancer Immunol Immun-
other 42:297–302
18. Osanai K, Iguchi M, Takahashi K, Nambu Y, Sakuma T, Toga
H, Ohya N, Shimizu H, Fisher JH, Voelker DR (2001)
Expression and localization of a novel Rab small G protein
(Rab38) in the rat lung. Am J Pathol 158:1665–1675
19. Osanai K, Takahashi K, Nakamura K, Takahashi M, Ishigaki
M, Sakuma T, Toga H, Suzuki T, Voelker DR (2005) Expres-
sion and characterization of Rab38, a new member of the Rab
small G protein family. Biol Chem 386:143–153
20. Parker JM, Guo D, Hodges RS (1986) New hydrophilicity
scale derived from high-performance liquid chromatography
peptide retention data: correlation of predicted surface
residues with antigenicity and X-ray-derived accessible sites.
Biochemistry 25:5425–5432
21. Pereira-Leal JB, Seabra MC (2001) Evolution of the Rab
family of small GTP-binding proteins. J Mol Biol 313:889–901
22. Pupa SM, Menard S, Andreola S, Colnaghi MI (1993) Anti-
body response against the c-erbB-2 oncoprotein in breast
carcinoma patients. Cancer Res 53:5864–5866
23. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T,
Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M
(1995) Human neoplasms elicit multiple speciWc immune
responses in the autologous host. Proc Natl Acad Sci USA
92:11810–11813
24. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis
genes: review, standardization, and commentary. Cancer
Immun 4:1
25. Schauer U, Stemberg F, Rieger CH, Buttner W, Borte M,
Schubert S, Mollers H, Riedel F, Herz U, Renz H, Herzog W
(2003) Levels of antibodies speciWc to tetanus toxoid, Haemo-
philus inXuenzae type b, and pneumococcal capsular polysac-
charide in healthy children and adults. Clin Diagn Lab
Immunol 10:202–207
26. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach
J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral
immune response of cancer patients to a panel of human
tumor antigens. J Exp Med 187:1349–1354
27. Takahashi M, Chen W, Byrd DR, Disis ML, Huseby ES, Qin
H, McCahill L, Nelson H, Shimada H, Okuno K, et al (1995)
Antibody to ras proteins in patients with colon cancer. Clin
Cancer Res 1:1071–1077
28. Van den Eynde BJ, van der Bruggen P (1997) T cell deWned
tumor antigens. Curr Opin Immunol 9:684–693
29. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF,
Carbone DP (1992) Development of antibodies against p53 in
lung cancer patients appears to be dependent on the type of
p53 mutation. Cancer Res 52:4168–4174
30. Yamamoto A, Shimizu E, Ogura T, Sone S (1996) Detection
of auto-antibodies against L-myc oncogene products in sera
from lung cancer patients. Int J Cancer 69:283–289
31. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu
YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, et al
(2005) Dominant B cell epitope from NY-ESO-1 recognized
by sera from a wide spectrum of cancer patients: implications
as a potential biomarker. Int J Cancer 114:268–273
32. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D,
Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N,
Mackensen A, et al (2004) EVector function of human tumor-
speciWc CD8 T cells in melanoma lesions: a state of local
functional tolerance. Cancer Res 64:2865–2873123
